Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease
Article first published online: 26 FEB 2013
© 2013 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 7, pages 720–729, April 2013
How to Cite
Aliment Pharmacol Ther 2013; 37: 720–729
- Issue published online: 5 MAR 2013
- Article first published online: 26 FEB 2013
- Accepted manuscript online: 25 FEB 2013 12:00AM EST
- Manuscript Accepted: 29 JAN 2013
- Manuscript Revised: 16 JAN 2013
- Manuscript Revised: 7 DEC 2012
- Manuscript Received: 19 NOV 2012
Elevated iron indices are described in non-alcoholic fatty liver disease and iron reduction has been suggested as a potential therapy.
To determine whether phlebotomy is an effective therapy for non-alcoholic fatty liver disease.
Patients with biopsy proven non-alcoholic fatty liver disease underwent baseline evaluation to determine severity of metabolic and liver disease. A Phase II trial of phlebotomy was carried out to achieve near-iron depletion (serum ferritin ≤50 μg/L or haemoglobin 100 g/L). Repeat liver biopsy, anthropometric and biochemical measurements were performed 6 months following the end of treatment. Primary outcome was improvement in liver histology, assessed using the non-alcoholic fatty liver disease activity score.
Thirty-one patients completed follow-up. Iron reduction resulted in a significant improvement in the non-alcoholic fatty liver disease activity score (−0.74 ± 1.83, P = 0.019). Reductions in individual histological features of lobular inflammation (−0.29 ± 1.07, P = 0.182), steatosis (−0.26 ± 0.82, P = 0.134), hepatocyte ballooning (−0.19 ± 0.70, P = 0.213) did not achieve significance nor did the score for fibrosis (−0.32 ± 0.94, P = 0.099).
This prospective Phase II study of phlebotomy with paired liver biopsies evaluating phlebotomy therapy in non-alcoholic fatty liver disease patients suggests that iron reduction may improve liver histology. However, the effect size of phlebotomy raises questions of whether treatment could have sufficient clinical significance to justify a definitive Phase III trial. This trial has been registered with the US National Institute of Health (clinicaltrials.gov, Identifier NCT 00641524).